Email updates

Keep up to date with the latest news and content from Virology Journal and BioMed Central.

Open Access Open Badges Short report

A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011

Bin Yu12, Zhen Wang1, Jianing Dong1, Chu Wang1, Lina Gu3, Caijun Sun4, Wei Kong12* and Xianghui Yu12*

Author Affiliations

1 National Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin University, Changchun, 130012, China

2 Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, College of Life Science, Jilin University, Changchun, 130012, China

3 Department of ICU, The First Hospital of Jilin University, Jilin University, Changchun, 130021, China

4 State Key Laboratory of Respiratory Diseases, Center for Infection & Immunity, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China

For all author emails, please log on.

Virology Journal 2012, 9:287  doi:10.1186/1743-422X-9-287

Published: 23 November 2012



Efficacy of recombinant adenovirus serotype 5 (rAd5) vaccine vectors for human immunodeficiency virus type 1 (HIV-1) and other pathogens have been shown to be limited by high titers of pre-existing Ad5 neutralizing antibodies (NAbs) in the developing world.


Using a secreted embryonic alkaline phosphatase (SEAP) neutralization assay, 50% serum neutralization titers against rAd2 and rAd5 vectors were measured in samples from 274 infants and young children in northeast China. The pediatric population was found to be 59.6% and 43.3% seropositive for rAd2 and rAd5, respectively. Of all participants, 44.9% had moderate and high (> 200) and 25.6% had high (>1000) Ad2 NAb titers, compared with the corresponding rates of 26.6% and 9.3% against Ad5. Marked age-dependent increases in NAb titers to both Ad serotypes were observed across five age groups, with the exception of infants in the 0-6-month group commonly having relatively high titers due to pre-existing maternal antibodies.


Our data suggest that Ad-based therapies may be suitible for children in the 7-12-month age range in this region.

Adenovirus; Seroprevalence; Neutralizing antibodies; HIV vaccine